Navigation Links
4Dx Announces Preliminary Clinical Trial Data at Prestigious World Lung Imaging Event
Date:3/9/2017

MELBOURNE, Australia, March 9, 2017 /PRNewswire/ -- 4Dx has publicly released preliminary clinical study data at the prestigious World Lung Imaging Workshop at the University of Pennsylvania. Founder and CEO, Dr. Andreas Fouras, was invited to deliver the latest data to world leaders in lung imaging and pulmonary medicine. This globally recognised event brings together leaders at the forefront of the industry to present and share the latest developments in lung imaging.

"The quality of the imaging is spectacular," said Debiao Li, PhD, Director of the Cedars-Sinai Biomedical Imaging Research Institute and Professor of Biomedical Sciences at Cedars Sinai where the study is being conducted."This technology will give us unique capabilities."

4Dx's software technology provides accurate and sensitive data with a unique 4-dimensional perspective to clinical practitioners, and has been extensively validated in pre-clinical studies. The technology has the potential to provide more information, and faster validation of treatment with reduced exposure, while also allowing for earlier detection of disease.

The announcement of these results by 4Dx, demonstrates compelling evidence of the leap from the laboratory to the clinic, opening the door for huge market potential as 4Dx continues to engage with leading U.S hospitals.  

4Dx technology enables clinicians to capture images that effectively visualise and quantify motion of airflow at high resolution within the breathing lungs.  Within the $1.4 trillion respiratory healthcare sector, there are 162 million respiratory diagnostics procedures performed each year, for a clearly identified $30 billion per annum addressable market.

The public announcement of preliminary clinical data at this prestigious event is a huge milestone for the company, with 4Dx expecting increased interest from key clinical groups as well as investors.

Founder and CEO Andreas Fouras says "We are extremely thrilled to have been given the opportunity to present data that shows the potential of our technology to change the lives of millions through earlier and better informed intervention". 

Further information:
Sarah Kemter
Monsoon Communications
Mobile (+61) 407 162 530    
sarahk@monsoon.com.au  

About 4Dx:
4Dx is a software company aiming to deliver the global gold standard in respiratory diagnostics for all lung disorders, including, asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis and cancer.

The unique 4Dx technology accurately and quickly scans lung function as the patient breathes, to provide sensitive, early diagnosis, and to monitor changes over time. Our Software-as-a-Service scans deliver more complete information, revealing subtle variations in lung function down to the finest detail, all while using lower levels of radiation than traditional methods.

Respiratory diagnosis is a $30 billion p.a. global industry that 4Dx aims to disrupt and grow through technology that provides clinicians with greater insights into diseases of the lung.

4Dx will bring about a step change in lung health diagnostics by providing better information to doctors and patients.

Better information means better decisions, and better outcomes.

Monsoon Communications
Level 1, 121 Flinders Lane
Melbourne VIC 3000
p: 03 9620 3333
e: info@monsoon.com.au
w: www.monsoon.com.au

This message and its attachments may contain legally privileged or confidential information. It is intended solely for the named addressee. If you are not the addressee indicated in this message (or responsible for delivery of the message to the addressee), you may not copy or deliver this message or its attachments to anyone. Rather, you should permanently delete this message and its attachments and kindly notify the sender by reply e-mail. No warranty is made that the e-mail or attachment(s) are free from computer virus or other defect.

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/4dx-announces-preliminary-clinical-trial-data-at-prestigious-world-lung-imaging-event-300420847.html


'/>"/>
SOURCE 4Dx
Copyright©2017 PR Newswire.
All rights reserved


Related biology news :

1. Aware, Inc. Announces Resignation of co-Chief Executive Officer & Chief Financial Officer
2. Acuant Announces Best-In-Class Data Capture and Multi-Factor Verification Solutions Addressing Rising Identity Fraud in the Digital Economy
3. Securus Announces the Appointment of a Director of Recidivism and Reentry
4. MedNet Solutions Announces Latest Release Of Its Award-Winning eClinical Solution
5. IDTechEx Research Announces New Report on Sensors for Robotics
6. Crossmatch Announces Foreign Assistance/Disaster Relief Solution to Combat Fraud, Waste and Abuse
7. Trovagene Announces Broadening Network of Commercial Distributors
8. SomaLogic announces that it has joined the iCarbonX Digital Life Alliance
9. Cloudtag Announces Onitor Track, a Weight Loss Program and Wearable for the Age of Data, at the 2017 Consumer Electronics Show
10. AIC Announces Release of New White Paper on Using NVMe Storage Servers to Build High-performance, Scale-out Storage for HPC Applications
11. Synthetic Biologics Announces Pricing of Public Offering of Common Stock and Warrants
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/21/2017)... PORTLAND, Ore. , Feb. 22, 2017 /PRNewswire/ ... of Companies (Avamere Health Services, Infinity Rehab, Signature Hospice, ... study that will apply the power of IBM cognitive ... and health centers. By analyzing data streaming from sensors ... into physical and environmental conditions, and obtain deeper learnings ...
(Date:2/14/2017)... -- Wake Forest Baptist Medical Center today announced Julie Ann Freischlag, ... (CEO). Freischlag joins the medical center on May 1 ... who last year announced that he would transition to ... it since 2008.   As CEO, Freischlag ... academic health system, which includes Wake Forest School of ...
(Date:2/10/2017)... Research and Markets has announced the addition of ... Commercial Aspects" to their offering. ... Biomarkers play an important ... selection of treatment as well for monitoring the results. There ... modern medicine. Biochip/microarray technologies and next generation sequencing are also ...
Breaking Biology News(10 mins):
(Date:3/28/2017)... ... March 28, 2017 , ... ... release of LabKey’s newest software solution, LabKey Biologics . Built in collaboration ... and biotech organizations, LabKey Biologics provides drug research teams tools for biological entity ...
(Date:3/28/2017)... Life Sciences Inc. (OTCQB: REPCF) (TSXV: RP) (FRA:P6P2) ("RepliCel" or ... data from its phase 1/2 tendon repair study investigating the ... as a treatment for Achilles tendinosis. ... The clinical trial met ... months and showed no serious adverse events related to the ...
(Date:3/27/2017)... ... 27, 2017 , ... IsoPlexis Corporation (IsoPlexis), a venture capital-funded ... more through a single-cell precision engineering platform, today announced it has received an ... the laboratory of Dr. James Heath at the California Institute of Technology, a ...
(Date:3/27/2017)... 27, 2017  The global market for clinical ... to a new report from Kalorama Information.  In ... performed to evaluate disease progression, monitor drug treatment ... reasons.  The healthcare market research firm,s report, ... an overview of the medical laboratory industry and ...
Breaking Biology Technology: